Cationic solid lipid nanoparticles loaded by cystein proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: Characterization and in vitro evaluations

Doroud, Delaram; Vatanara, Alireza; Zahedifard, Farnaz; Gholami, Elham; Vahabpour, Rouhollah; Najafabadi, Abdolhossein Rouholamini; Rafati, Sima

doi:10.1016/j.jconrel.2010.07.079

Cited by 18 publications

(28 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As gene delivery systems, SLNs have been studied over the last years for a large number of diseases [46, 60, 61] and different routes of administration [62]. Cationic lipids are used to prepare SLNs due to their positive surface charge that interacts electrostatically with the negative charge of the nucleic acids.…”

Section: Lipid Nanoparticles (Lnp)mentioning

confidence: 99%

Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives

Torrecilla

Rodríguez-Gascón

Solinís

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

The efforts made to develop RNAi-based therapies have led to productive research in the field of infections in humans, such as hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), human cytomegalovirus (HCMV), herpetic keratitis, human papillomavirus, or influenza virus. Naked RNAi molecules are rapidly digested by nucleases in the serum, and due to their negative surface charge, entry into the cell cytoplasm is also hampered, which makes necessary the use of delivery systems to exploit the full potential of RNAi therapeutics. Lipid nanoparticles (LNP) represent one of the most widely used delivery systems for in vivo application of RNAi due to their relative safety and simplicity of production, joint with the enhanced payload and protection of encapsulated RNAs. Moreover, LNP may be functionalized to reach target cells, and they may be used to combine RNAi molecules with conventional drug substances to reduce resistance or improve efficiency. This review features the current application of LNP in RNAi mediated therapy against viral infections and aims to explore possible future lines of action in this field.

show abstract

Section: Lipid Nanoparticles (Lnp)mentioning

confidence: 99%

Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives

Torrecilla

Rodríguez-Gascón

Solinís

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Their data claimed it as a promising DNA vaccine carrier and it can overcome the main drawback of naked pDNA delivery that is rapidly eliminated from the circulation. 103 Inorganic Nanoparticles for DNA Vaccine Delivery The inorganic nanoparticles have emerged with their variety and possible applications in material sciences. The inorganic particles are accompanied with a number of advantages over organic particles.…”

Section: Recent Developments In Application Of Nanoparticles In Dna Vmentioning

confidence: 99%

Nanoparticles for DNA Vaccine Delivery

Shah¹,

He²,

Li³

et al. 2014

j biomed nanotechnol

View full text Add to dashboard Cite

Nanotechnology is the development of engineered devices or materials at the micro molecular level in the nanometer range. The properties of nanoparticles that these could be designed, manufactured and introduced into the human body, have led to its application in various fields of medicine. They are being used for construction of diagnostic devices, contrast agents, analytical tools, physical therapy, drug discovery and drug delivery vehicles. The DNA vaccines have been emerged as best remedy for problematic diseases being capable of producing humoral and cellular immune responses as well as the safest vaccines so far. There are a large number of infectious diseases against which traditional vaccines failed to respond effectively. Especially, viral diseases and cancer where DNA vaccines seem to be the better option. However, the magnitude of immune responses produced by them in primates is not sufficient to be used in human beings. There is an evidence that these immune responses can be augmented by using properly structured nano-sized particles that may avoid DNA degradation and facilitate targeted and controlled delivery to antigen presenting cells. Adsorption, formulation or encapsulation with particles has been found to stabilize DNA formulations. The use of nanoparticles for vaccine delivery is a platform technology and has been applied for delivery of a variety of existing and potential vaccines successfully.

show abstract

“…The cSLN suspension was manufactured by a validated technique previously described by Doroud et al (22). cSLN-pDNA complexes were prepared by adding volumes corresponding to 1200 lg of purified pDNA (pcDNA-A2-CPA-CPB ÀCTE ) to cSLN suspension at DOTAP: pDNA ratio of 6 : 1 (w/w) and at 60 min incubation at room temperature separately (22,24). Complete condensation and complexation of pDNAs with cSLN were analysed by agarose gel electrophoresis, as previously demonstrated (22,24).…”

Section: Csln Preparation Vaccine Formulation Characterization and mentioning

confidence: 99%

“…cSLN-pDNA complexes were prepared by adding volumes corresponding to 1200 lg of purified pDNA (pcDNA-A2-CPA-CPB ÀCTE ) to cSLN suspension at DOTAP: pDNA ratio of 6 : 1 (w/w) and at 60 min incubation at room temperature separately (22,24). Complete condensation and complexation of pDNAs with cSLN were analysed by agarose gel electrophoresis, as previously demonstrated (22,24). Size and zeta potential measurements, gel retardation analysis and DNase I protection study were all performed according to the conditions demonstrated in our previous study (22,24).…”

Section: Csln Preparation Vaccine Formulation Characterization and mentioning

confidence: 99%

“…However, there are limited data to compare the efficiency of the electroporation and chemical delivery systems in the context of a vaccine production. In our previous studies, the use of cationic solid-lipid nanoparticle (cSLN) formulation as a delivery system has revealed comparable efficiency: cytotoxicity ratio with linear PEI-25 kDa-pDNA polyplexes, protected CPA, CPB and CPB ÀCTE genes from extracellular enzymatic degradation and also exhibited considerable low cytotoxicity (22). Hence, cSLNs can be considered as suitable adjuvant and/or delivery system for designing third-generation cocktail vaccines.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cationic solid–lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice

Saljoughian

Zahedifard

Doroud

et al. 2013

Parasite Immunology

View full text Add to dashboard Cite

The use of an appropriate delivery system has recently emerged as a promising approach for the development of effective vaccination against visceral leishmaniasis (VL). Here, we compare two vaccine delivery systems, namely electroporation and cationic solid-lipid nanoparticle (cSLN) formulation, to administer a DNA vaccine harbouring the L. donovani A2 antigen along with L. infantum cysteine proteinases [CPA and CPB without its unusual C-terminal extension (CPB(-CTE) )] and evaluate their potential against L. infantum challenge. Prime-boost administration of the pcDNA-A2-CPA-CPB(-CTE) delivered by either electroporation or cSLN formulation protects BALB/c mice against L. infantum challenge and that protective immunity is associated with high levels of IFN-γ and lower levels of IL-10 production, leading to a strong Th1 immune response. At all time points, the ratio of IFN-γ: IL-10 induced upon restimulation with rA2-rCPA-rCPB and F/T antigens was significantly higher in vaccinated animals. Moreover, Th2-efficient protection was elicited through a high humoral immune response. Nitric oxide production, parasite burden and histopathological analysis were also in concordance with other findings. Overall, these data indicate that similar to the electroporation delivery system, cSLNs as a nanoscale vehicle of Leishmania antigens could improve immune response, hence indicating the promise of these strategies against visceral leishmaniasis.

show abstract

Cationic solid lipid nanoparticles loaded by cystein proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: Characterization and in vitro evaluations

Cited by 18 publications

References 2 publications

Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives

Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives

Nanoparticles for DNA Vaccine Delivery

Cationic solid–lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice

Contact Info

Product

Resources

About